Botulism overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Michael Maddaleni, B.S., Keanu Ngo[2]

Overview

Botulism is a neuroparalytic illness caused by botulinum neurotoxin (BoNT), a potent neurotoxin produced primarily by Clostridium botulinum and, rarely, by neurotoxigenic C. butyricum and C. baratii. BoNT blocks acetylcholine release at presynaptic cholinergic nerve terminals, producing flaccid paralysis involving somatic and autonomic neuromuscular junctions.

Mechanism

BoNT enters presynaptic cholinergic nerve terminals and prevents acetylcholine release by proteolytic disruption of SNARE proteins. The resulting neuromuscular blockade produces cranial-nerve dysfunction, descending skeletal-muscle paralysis, autonomic dysfunction, and potentially respiratory failure. Detailed toxin structure, SNARE targets, and neuronal recovery mechanisms are addressed in the Pathophysiology microchapter.

Clinical forms

Four naturally occurring forms are recognized according to the route of toxin acquisition:

• Infant botulism — intestinal colonization with in situ toxin production in infants younger than 12 months, occurring predominantly before 6 months of age, with median onset at approximately 4 months.
• Foodborne botulism — ingestion of preformed BoNT, classically from improperly preserved, fermented, or home-canned foods.
• Wound botulism — wound colonization with in situ toxin production; strongly associated with injection drug use.
• Adult intestinal colonization botulism — rare intestinal colonization with in situ toxin production in adults.

Non-natural forms include iatrogenic botulism following excessive therapeutic or cosmetic BoNT exposure and inhalational botulism.

Clinical syndrome

The characteristic syndrome is acute, afebrile, symmetric, descending flaccid paralysis beginning with cranial-nerve dysfunction in an alert patient with preserved sensorium. Early manifestations may include diplopia, blurred vision, ptosis, dysarthria, dysphonia, and dysphagia. Weakness may then descend to involve the trunk and limbs and progress to respiratory failure. Autonomic manifestations can include dry mouth, ileus or constipation, pupillary abnormalities, and blood-pressure or heart-rate lability.

Infant botulism commonly presents with constipation, poor feeding or weak suck, weak cry, ptosis, diminished gag reflex, loss of head control, and progressive hypotonia.

Epidemiology and incubation

Botulism is rare. Reported annual United States case counts vary by surveillance period and source. Infant botulism constitutes the majority of reported cases, with foodborne and wound botulism accounting for smaller proportions.

Surveillance studies have demonstrated broader geographic recognition and reporting of infant botulism, while the extent to which this reflects changes in true incidence remains uncertain.

For foodborne botulism, symptom onset typically occurs approximately 2 hours to 8 days after exposure, with onset often occurring around 48 hours.

Diagnosis

Diagnosis is fundamentally clinical. The combination of acute cranial-nerve dysfunction followed by symmetric descending weakness in an alert, generally afebrile patient should prompt consideration of botulism. Routine laboratory studies, cerebrospinal fluid examination, and neuroimaging are generally used to evaluate alternative diagnoses rather than to establish botulism.

Confirmatory testing may include detection of BoNT, toxin neutralization assays, culture, mass spectrometry, or nucleic acid amplification through public-health or reference laboratories. Results may take days; treatment should not be delayed while awaiting laboratory confirmation.

See Laboratory findings, Other diagnostic studies, and Differentiating for detailed diagnostic evaluation.

Treatment

Management has two principal components: early passive immunization with botulinum antitoxin and meticulous supportive care, particularly respiratory and nutritional support.

• Infant botulism caused by toxin types A or B: human-derived botulism immune globulin intravenous (BIG-IV; BabyBIG), obtained through the California Infant Botulism Treatment and Prevention Program.
• All other forms and ages: equine-derived heptavalent botulinum antitoxin (BAT/HBAT), directed against serotypes A–G, obtained through the CDC. HBAT is also used for type F infant botulism and for foodborne or wound botulism occurring in an infant when indicated.
• Antitoxin neutralizes circulating toxin and prevents further neuronal uptake but does not reverse established paralysis. Benefit is greatest when treatment is administered within 48 hours of symptom onset, ideally within 24 hours, and declines with delay. Antitoxin should still be administered when clinically indicated even if more than 48 hours have elapsed.
• Supportive care includes close monitoring for respiratory failure, airway protection, mechanical ventilation when required, and nutritional support.
• Routine antibiotics are not indicated for foodborne or infant botulism. Antibiotic therapy may be used for wound botulism after antitoxin administration and for secondary infections.
• Aminoglycosides and clindamycin should be avoided/contraindicated when botulism is suspected because they can potentiate botulinum neuromuscular blockade and precipitate respiratory arrest.

Botulism is a notifiable condition requiring urgent public-health coordination. Suspected cases should prompt immediate consultation with the state or local health department for diagnostic testing and antitoxin access.

Detailed dosing, contraindications, adverse effects, monitoring, and adjunctive therapy are addressed in the Medical therapy microchapter.

Prognosis

Historical case-fatality rates were approximately 60% in the 1950s, compared with approximately 3%–5% with modern diagnosis, intensive care, and antitoxin therapy. Recovery of neuromuscular function generally occurs but may require weeks to months.

Detailed natural history, complications, predictors of outcome, and mortality are addressed in the Natural history, complications, and prognosis microchapter.

High-yield clinical points

• Consider botulism when acute, symmetric, descending weakness begins with cranial-nerve dysfunction in an alert, afebrile patient.
• Preserved sensorium and descending weakness are important clinical clues.
• Do not wait for confirmatory laboratory testing before administering antitoxin when clinical suspicion is sufficient.
• Monitor closely for respiratory failure because neuromuscular weakness may progress despite preserved mental status.
• Antitoxin prevents additional toxin-mediated neuronal injury but does not reverse established paralysis.
• Select the antitoxin according to the clinical form and toxin type rather than age alone.
• Avoid aminoglycosides and clindamycin because of their potential to worsen neuromuscular blockade.

Common pitfalls

• Waiting for confirmatory laboratory testing before initiating antitoxin.
• Misdiagnosing botulism as Myasthenia gravis or Guillain-Barré syndrome.
• Failing to anticipate respiratory failure.
• Selecting BabyBIG for an infant with a form of botulism for which HBAT is indicated.
• Administering aminoglycosides or clindamycin to a patient with suspected botulism.
• Using routine antibiotics in foodborne or infant botulism.
• Assuming infant botulism is attributable only to a specific food exposure rather than considering environmental exposure.